• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Year 2019

Article

The Center for Biosimilars® recaps the top stories for the year 2019.

Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the year 2019.

Number 5: In January, Pfizer confirmed that it made the decision to terminate 5 preclinical biosimilar programs after the results of the company’s annual investment review.

Number 4: Also in January, the FDA approved Samsung Bioepis’ Ontruzant, a biosimilar trastuzumab referencing Herceptin.

Number 3: In August, UnitedHealthcare indicated that it would prefer 2 oncology biosimilars in its commercial and community plans.

Number 2: In May, the FDA released its long-awaited final guidance on demonstrating interchangeability of a biosimilar with its reference.

Number 1: Finally, the US market got its first anticancer biosimilars in July when Amgen and Allergan launched biosimilar bevacizumab and trastuzumab.

To read all of these articles and more, visit centerforbiosimilars.com.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Canavan & O’Dell
global biosimilars week join the movement
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Related Content
© 2025 MJH Life Sciences

All rights reserved.